mProX™ Human GDF15 Stable Cell Line

Muruganandam, Maheswari. et al. "Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis." Journal of inflammation research, 2023.
Systemic sclerosis (SSc) is a complex autoimmune disease with vascular damage, vasoinstability, and decreased perfusion, leading to inflammation and fibrosis of the skin and internal organs. Biomarkers are important indicators of the disease processes within an individual and their accurate and reproducible measurement is crucial. The field of biomarkers in SSc is extensive, with over 240 pathways and proteins being implicated in the disease's development. Anti-nuclear antibodies (ANA) are classical biomarkers, with well-defined clinical classifications and are present in more than 90% of SSc patients. Transforming growth factor-β (TGF-β) is a central biomarker in SSc's fibrotic process, along with other newly identified biomarkers such as tyrosine kinases, interferon-1 signaling, IL-6 signaling, endogenous thrombin, PPARs, lysophosphatidic acid receptors, and amino acid metabolites. Several other biomarkers, including STAT4, CD226, IRF5, IRAK1, CTGF, NLRP1, CD3ζ, and the NLR family, have been implicated in a subtype of SSc called SSc-ILD. Genetic factors, including HLDRB1 alleles, also play a significant role in SSc. The role of various interleukins and chemokines (CCL, CXC, and CX3CL1) have also been identified as potential biomarkers, along with adiponectin and maresin-1, which are reduced in SSc patients. To determine disease activity and response to therapy, there has been a recent trend of using biomarker panels with complex multifactor analysis, machine learning, and artificial intelligence. This review discusses the various biomarkers involved in the pathology of SSc, including molecules, pathways, and receptors.
Muruganandam, Maheswari. et al. "Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis." Journal of inflammation research, 2023.
Pubmed: 37868834   DOI: 10.2147/JIR.S379815

Hooshmand-Moghadam, Babak. et al. "Effects of soy milk ingestion immediately after resistance training on muscular-related biomarkers in older men: a randomized controlled trial." Biology of sport, 2023.
The study aimed to investigate the impact of soy milk consumption on changes in body composition, strength, power, and biomarkers related to muscle function over a 12-week period of resistance training in older men. A total of 30 healthy older men (average age of 65.63 ± 3.16 years and body mass of 62.63 ± 3.86 kg) were randomly assigned to two groups: one receiving soy milk alongside resistance training (SR group) and the other receiving a placebo alongside resistance training (PR group). The SR group consumed 240 ml of non-dairy vanilla-flavored soy milk after each training session and on non-training days. Results showed significant differences in muscle mass, upper limb body strength (UBS), lower limb aerobic power (LAP), activin A, and GDF15 between the two groups (P < 0.05). Both groups experienced a significant decrease in body mass, body fat %, activin A, GDF15, and TGFβ1, as well as an increase in muscle mass, UBS, lower limb body strength, upper limb aerobic power, LAP, BDNF, and irisin compared to baseline (P < 0.05). The findings suggest that the consumption of soy milk during resistance training in older men can improve lean mass, strength, and power, and modulate the levels of skeletal muscle regulatory markers.
Hooshmand-Moghadam, Babak. et al. "Effects of soy milk ingestion immediately after resistance training on muscular-related biomarkers in older men: a randomized controlled trial." Biology of sport, 2023.
Pubmed: 37867735   DOI: 10.5114/biolsport.2023.123894